Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
38slipping
Latest NAV
₹27.2943
as of 07 Aug 2026
AUM
—
Expense ratio
—
Inception
14 May 2026
FundScore
38/100slipping
Rank #186 of 322 · top 62%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
4.51%
3M
10.36%
6M
21.19%
1Y
22.86%
3Y CAGR
19.96%
5Y CAGR
13.41%
Since incep.
13.37%
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap57.0%
Mid cap35.9%
Small cap7.1%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 31 May 2026.
Sun Pharmaceutical Industries Limited
equity
21.42%
Divi's Laboratories Limited
equity
9.53%
Dr. Reddy's Laboratories Limited
equity
8.93%
Cipla Limited
equity
8.86%
Lupin Limited
equity
6.18%
Laurus Labs Limited
equity
5.96%
Torrent Pharmaceuticals Limited
equity
5.19%
Aurobindo Pharma Limited
equity
4.48%
Glenmark Pharmaceuticals Limited
equity
3.85%
Alkem Laboratories Limited
equity
3.62%
Biocon Limited
equity
3.44%
Zydus Lifesciences Limited
equity
3.03%
Mankind Pharma Limited
equity
3.02%
IPCA Laboratories Limited
equity
2.38%
Gland Pharma Limited
equity
2.01%
JB Chemicals & Pharmaceuticals Limited
equity
2.00%
Wockhardt Limited
equity
1.89%
Abbott India Limited
equity
1.57%
Ajanta Pharma Limited
equity
1.39%
Piramal Pharma Limited
equity
1.20%